Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785366 · ClinicalTrials.gov registry record · Phase 3
A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)
A Phase 3 study, sponsored by Sebela Women's Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT03785366 is a Phase 3 study that has completed, run by Sebela Women's Health. The registered enrollment target is 41 participants.
The verdict
NCT03785366, a Phase 3 study, has completed, sponsored by Sebela Women's Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
Interventions
- DRUG VeraCept
- DRUG ParaGard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-12-17 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03785366
The ClinicalTrials.gov registry entry for NCT03785366 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sebela Women's Health, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VeraCept is the first listed.
NCT03785366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03785366 about?
NCT03785366 is a clinical study titled "A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)". to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
What is the current status of trial NCT03785366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2018-12-17. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT03785366?
The interventions under investigation include: VeraCept (DRUG), ParaGard (DRUG).
Who is sponsoring clinical trial NCT03785366?
This trial is sponsored by Sebela Women's Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.